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ABSTRACT
The Wilms tumor gene WT1 encodes a zinc-finger
transcription factor that is inactivated in a subset
of pediatric kidney cancers. During embryogenesis,
WT1 is expressed in a time- and tissue-specific
manner in various organs including gonads and
kidney but also in the hematopoietic system.
Although widely regarded as a tumor suppressor
gene, wild-type WT1 is overexpressed in a variety
of hematologic malignancies, most notably in acute
lymphoblastic leukemia as well as myelodysplastic
syndromes. Reduction of WT1 expression levels
leads to decrease of proliferation and apoptosis of
leukemic cells, suggesting that in certain contexts
WT1 might act as an oncogene. We show here that
histone deacetylase inhibitors like Trichostatin A
(TSA) can promptly and dramatically downregulate
Wt1 expression levels in different cell lines. This
effect was mostly due to the cessation of transcrip-
tion and was mediated by sequences located in
intron 3 of Wt1. In addition, TSA also caused
enhanced degradation of the Wt1 protein by the pro-
teasome. This was at least in part due to induction
of the ubiquitin-conjugating enzyme UBCH8. Thus,
downregulation of Wt1 expression might contribute
to the beneficial effects of histone deacetylase inhi-
bitors that are currently used in clinical trials as
cancer therapeutics.
INTRODUCTION
The Wilms tumor gene WT1 was originally identiﬁed as a
tumor suppressor gene lost in 10–15% of Wilms tumors
(1,2) and is a member of the GC- rich TATA-less and
CCAAT-less class of RNA pol II genes (3). The WT1
transcript encompasses 3.5kb and encodes a four zinc-
ﬁnger containing protein with an essential role in the
development of several organs, most notably the kidney
(4–6). More than 20 diﬀerent WT1 gene products with
molecular masses of 52–65kDa are generated by a com-
bination of alternative RNA splicing, the usage of diﬀer-
ent start codons and RNA editing (7).
Expression of the wild-type WT1 gene has been found
in most cases of acute myelocytic leukemia (AML), acute
lymphocytic leukemia (ALL), chronic myelocytic leuke-
mia (CML) and myelodysplastic syndrome (MDS) at
higher levels than those in normal bone marrow or per-
ipheral blood (8–10). WT1 is used as a prognostic factor
and marker for minimal residual disease in cases of acute
leukemia (9,11). Furthermore, various types of solid
tumors, including lung, breast, thyroid, esophageal and
colorectal cancers express wild-type WT1 at higher levels
compared to those in corresponding normal tissues (12).
In several studies, the role of Wt1 in cell proliferation,
diﬀerentiation and leukemogenesis has been analyzed.
In the chronic myeloid leukemia cell line K562 as well as
in primary leukemic cells from human patients, WT1
antisense oligomers inhibited growth via reduction of
WT1 protein levels (13). In the same cell line, ribozyme-
mediated downregulation of WT1 led to inhibition of
cell proliferation and apoptosis (14). Similarly, siRNA-
mediated reduction of WT1 mRNA levels in various leu-
kemic cell lines including those from AML and CML
patients inhibited proliferation and induced apoptosis
(15). Taken together, all these studies indicate that Wt1
may be necessary for leukemic or solid tumor growth sur-
vival and that under certain circumstances Wt1 could act
as an oncogene (12). This is corroborated by the recent
observation in mice that the chimeric oncoprotein AML1-
ETO exerts its leukemogenic function in cooperation with
Wt1 expression (16).
Conversely, removal of WT1 may have an anticancer
eﬀect. That this is indeed the case was recently demon-
strated by vaccination of patients with AML, MDS as
well as lung or breast cancer with a WT1 peptide. WT1
vaccination led to an increase in WT1-speciﬁc cytotoxic T
lymphocytes and subsequent cancer regression without
*To whom correspondence should be addressed. Tel: +49 3641 656042; Fax: +49 3641 656040; Email: cenglert@fli-leibniz.de
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.damage to other normal tissues (17). Thus, in partic-
ular cancers WT1 could be a therapeutic target and down-
regulation of WT1 might be a promising anticancer
strategy.
For transcription to begin in eukaryotes, concerted
actions of multiple protein factors are required. The
major hurdle in activating transcription in vivo is the
highly compacted nature of chromatin, which prevents
access of the transcription machinery to the DNA tem-
plate. Posttranslational modiﬁcations of histones such as
acetylation, phosphorylation, methylation, ubiquitination,
ADP-ribosylation, sumoylation and biotinylation are
assumed to be important factors that control chromatin
accessibility and subsequent gene transcription. It is this
association between histone modiﬁcation and the activity
state of the chromatin for which the expression ‘histone
code’ has been coined (18).
The best understood modiﬁcation is acetylation of
core histones, which is carried out by histone acetyl trans-
ferases (HATs); the steady state levels of acetylation
are maintained by the opposing activities of HATs and
histone deacetylases (HDACs) (19). So far at least 18
HDACs have been identiﬁed in humans and have been
grouped into four diﬀerent classes (20). Class I members
(HDACs 1–3 and 8) are most closely related to the
Saccharomyces cerevisiae transcriptional regulator RPD3.
Class II HDACs (4–7, 9 and 10) display similarity to yeast
HDA1; class III comprises the NAD
+-dependent sirtuin
deacetylases SIRT 1–7 and class IV consists of proteins
related to the recently identiﬁed human HDAC11, which
shares features of both class I and II. HDACs associate
with a number of oncoproteins and tumor suppressors
and in case of their aberrant activation or inactivation
the concomitant HDAC activity can lead to undue changes
in gene expression and in turn to diseases, e.g. cancer (21).
This observation has stimulated the identiﬁcation and
characterization of HDAC inhibitors as means to counter-
act disease-associated aberrant gene expression.
Trichostatin A (TSA), a Streptomyces product was origi-
nally identiﬁed as a fungicidic antibiotic. It inhibits all
class I and II HDACs and has potent antiproliferative
properties in cancer cells (22,23). Diﬀerential display anal-
ysis revealed that expression of only 2–5% of genes in
TSA-treated cells is signiﬁcantly altered (24). The basis
for this gene selectivity is not yet understood, but it sug-
gests that only a highly restricted set of genes is sensitive to
changes in histone acetylation (25,26). Another HDAC
inhibitor, suberoylanilide hydroxamic acid (SAHA) inhi-
bits the growth of prostate cancer cells in culture as well as
in a xenograft model (27). Moreover, TSA also inhibits
hypoxia-induced angiogenesis in the Lewis lung carci-
noma model (28). Thus, histone deacetylases are promis-
ing drug targets and clinical trials using ﬁrst generation
HDAC inhibitors as anticancer reagents are currently
under way (29).
Here, we report the eﬀect of HDAC inhibitors like TSA
on Wt1 expression. TSA led to a drastic downregulation
of Wt1 mRNA levels in diﬀerent human and mouse cell
lines. This eﬀect was mostly due to a reduction of Wt1
transcription. In addition, TSA induced degradation of
Wt1 protein via the proteasome. This eﬀect was at least
in part mediated by the ubiquitin-conjugating enzyme
UBCH8.
MATERIALS AND METHODS
Cell linesand drug treatment
Mouse mesonephric M15 as well as Leydig like TM3 cells
and human embryonic kidney 293 cells were maintained in
DMEM, human chronic myelogenous leukemia K562
cells were kept in RPMI medium supplemented with
10% FCS (Gibco, Paisley, Pennsylvania, USA) at 378C
with 5% CO2. For drug studies, exponentially growing
cells were trypsinized, seeded at 40% conﬂuency, grown
for 24h and then treated with TSA (Sigma, St. Louis,
Missouri, USA), valproic acid (VPA, Sigma), SAHA
(Merck, Whitehouse Station, New Jersey, USA) or MS-
275 (Alexis Biochemicals, San Diego, California, USA)
for 24h. In actinomycin D (Sigma) experiments, cells
were pretreated with 4mM actinomycin D for 1h prior
to TSA addition.
In order to assess the requirement for ongoing protein
synthesis, M15 cells were treated with TSA (500nM) and
cycloheximide (50mg/ml) as described above for 20h.
Similarly, M15 cells were treated with TSA (500nM)
and/or lactacystine (10mM) (Sigma) for 6 and 20h. To
determine the half-life of Wt1 protein in the presence of
TSA (500nM), VPA (1.5mM) or SAHA (5mM), M15
cells were treated with inhibitors alone or in combination
with cycloheximide (50mg/ml). Cells were harvested at
indicated time points and used for further analysis.
RNA isolation and quantitative RT–PCR
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, California, USA) according to the manufac-
turer’s protocol. RNA samples were treated with DNase
RQ1 (Promega, Madison, Wisconsin, USA) to remove
any genomic DNA. cDNA was synthesized from 2mg
total RNA using the SuperScript II RT kit (Invitrogen).
Real-time PCR reaction was carried out employing the
QuantiTect SYBR green real-time PCR kit (Qiagen,
Hilden, Germany) on a Biorad iCycler in a 96-well
format. PCR conditions were: 958C for 15min, followed
by 40 cycles of three-step PCR including melting for 30s at
958C, annealing for 30s at 608C and elongation for 30s at
728C. Primers used were: Wt1F AGTTCCCCAACCA
TTCCTTC, Wt1R TTCAAGCTGGGAGGTCATTT, WT
1F CAGTTCCCCAACCACTCATT, WT1R AAGCTGG
GATGTCATTTGGT, UBCH8F GATGCCAATGTCC
TGGTGT, UBCH8R GCAAATCTGTCCGTTCTCGT,
 -ActinF TGTTACCAACTGGGACGACA,  -ActinR
GGGGTGTTGAAGGTCTCAAA, GAPDHF AACAGCG
ACACCCACTCCTC, GAPDHR GGAGGGGAGATTCA
GTGTGGT. Expression levels were determined in one
plate for all samples simultaneously and normalized to
the corresponding amounts of  -Actin or GAPDH cDNA
measured within the same plate. Relative expression levels
where calculated using the 2
 CT method (30).
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A total of 2 10
6 M15 cells (treated with 500nM TSA or
ethanol for 24h) were cross-linked with 1% formaldehyde
for 10min at 378C. Cells were resuspended in 250ml
SDA lysis buﬀer (1% SDS, 50mM Tris, pH 8.1, 10mM
EDTA, supplemented with protease inhibitors) followed
by sonication to an average DNA length of 200–1000bp.
The sample was cleared by centrifugation and diluted
10-fold in ChIP dilution buﬀer (0.01% SDS, 1.1%
Triton X-100, 1.2mM EDTA, 16.7mM Tris, pH 8.1 and
167mM NaCl, supplemented with protease inhibitors).
Aliquots of the diluted samples were kept as input controls.
Anti-acetylated histone H4 (AcH4) antibody (Upstate,
Charlottesville, Virginia, USA) was added to each tube,
which were rotated at 48C overnight. A total of 30 mlo f
protein A beads was then added to each of the tubes, which
were further rotated for 2h at 48C. The beads were washed
once with 1ml of the following buﬀers: (i) low salt immune
complex wash buﬀer (0.1% SDS, 1% Triton X-100, 2mM
EDTA, 20mM Tris, pH 8.1 and 150mM NaCl); (ii) high
salt immune complex wash buﬀer (0.1% SDS, 1% Triton
X-100, 2mM EDTA, 20mM Tris, pH 8.1 and 500mM
NaCl); (iii) LiCl immune complex wash buﬀer (0.25M
LiCl, 1% NP-40, 1% deoxycholic acid, 1mM EDTA and
10mM Tris, pH 8.1) and (iv) TE buﬀer (10mM Tris,
pH 8.1, 1mM EDTA). The beads were eluted with 250ml
of elution buﬀer (1% SDS, 0.1M NaHCO3) and incubated
overnight at 658C to reverse cross-links. The eluates were
treated with proteinase K and extracted with phenol/
chloroform followed by ethanol precipitation. The DNA
was dissolved in TE buﬀer and analyzed by PCR.
The following PCR primers were used; promoter:
CCTCCTGGCTCCTCCTCTT (sense) and CGCTGCCT
TGAACTCCTTAC (antisense); intron (688–847): AGA
TTGGGTGGGGGAATG (sense) and CCAAGGATGGG
AGAGAAAGA (antisense); intron (2015–2212): CACTT
GCATCTTTGGTGCTT (sense) and TTGCTCCCATTT
TCTCTGCT (antisense); intron (5478–5614): TAGCT
TCGGAGTCCATTTCC (sense) and GTGTCTGCGTCC
CTCACC (antisense); intron (8658–8758): TGTAATGAC
CCTGTCACGAA (sense) and GTTACACGGGCTGGAC
AACT (antisense). PCR products were ampliﬁed for 32
cycles.
Immunoblot analysis
Cells were harvested, washed with PBS and lyzed in ice-
cold protein lysis buﬀer (50mM Tris pH 7.6, 400mM
NaCl, 0.5% NP-40, 1mM PMSF and 1 protease inhibi-
tor cocktail (Roche, Mannheim, Germany)). Lysates were
clariﬁed by centrifugation (15000g for 15min at 48C) and
the supernatant was analyzed immediately or stored at
 808C. Equivalent amounts of protein (25–40mg) were
resolved by 10–12% SDS–PAGE and transferred onto a
PVDF membrane (Hybond P, Amersham Biosciences,
Piscataway, New Jersey, USA). Membranes were incu-
bated with anti-Wt1 (1:1000, Santa Cruz, California,
USA) anti-b-Actin (1:5000, Sigma), anti-acetylated his-
tone H4 (1:5000, Upstate) anti-UBE2L6 (1:1000,
Abgent, San Diego, California, USA), anti-HA (1:1000,
Cell Signaling, Danvers, Massachusetts, USA) or anti-V5
(1:10000, Invitrogen) primary antibodies overnight at 48C.
Blots were then incubated with horseradish peroxidase-
conjugated secondary antibody. Bands were visualized
by enhanced chemiluminescence (Amersham Pharmacia,
Uppsala, Sweden) followed by exposure to autoradiogra-
phy ﬁlm (Amersham Pharmacia). To detect acetylated his-
tone H4, cells were lyzed in protein loading buﬀer
(0.313M Tris pH 6.8, 10% SDS, 40% glycerol, 0.05%
bromophenol blue and 2% b-ME) and sonicated three
times for 20s each and separated on 15% SDS–PAGE.
Quantiﬁcation of immunoreactive bands on ﬁlms was per-
formed using the Bio-Rad Quantity One Software pro-
gram. Values for Wt1 were divided by those for b-Actin
and are depicted as percent relative to the control set as
100%.
In vivo ubiquitination assay was performed as described
(31). Ubiquitinated Wt1 was detected by western blotting
using an anti-HA antibody.
Nuclear run-off assay
Nuclear run-oﬀ assay was performed as described (32).
Radiolabeled RNA was hybridized with a Hybond-N
nylon membrane (Amersham) containing immobilized
fragments of Gapdh (1mg of a 558bp fragment) and Wt1
(2mg of a EcoRI-ApaI fragment). Hybridization was per-
formed overnight at 658C with 1 10
6c.p.m. labeled RNA
per sample using 2ml of the Rapid-hyb buﬀer
(Amersham) according to the manufacturer’s recommen-
dations. To quantitate the signals, radioactive spots were
excised from the membranes and measured in a scintilla-
tion counter.
Constructs, transfection andreporter geneassay
For the Wt1 promoter construct, a 3318bp Wt1 upstream
fragment was ampliﬁed by PCR with primers
mWt1F2KpnI aCGTGGTACCGCCAGTGTCTCTTTTC
TTCCA and P1XhoI ACGTCTCGAGCGCTG CCTTGA
ACTCCTTACC containing a KpnI and an XhoI restric-
tion site, respectively, using a PAC clone harboring the
entire Wt1 genomic locus (33). PCR was performed
as mentioned above except elongation was carried out
for 3min at 728C using Triple-Master enzyme mix
(Eppendorf, Hamburg, Germany). PCR products were
gel puriﬁed and ligated into the pGEMT-Easy vector
(Promega). The promoter fragment was removed from
the vector by XhoI/KpnI digestion and cloned into
pGL3-Basic. Cloning of Wt1 intron 1 and intron 3 into
the pGEMT-Easy vector has been described (33). After
excision with NotI and subsequent ﬁll-in reaction by
Klenow enzyme, introns 1 and 3 were cloned into a
SmaI-linearized and dephosphorylated pGL3-Promoter
vector to create pGL3Int1 and pGL3Int3, respectively.
For short-term stable transfections, 2 10
6 M15 cells
were transfected with 10mg of reporter plasmid or the
respective empty vector (pGL3-Basic or pGL3-Promoter)
as control, along with 1mg of pBABE-puro using
SuperFect (Qiagen) according to the manufacturer’s
recommendations. Selection was started after 24h using
1mg puromycin/ml. At day 5 after transfection, 1 10
5
cells of the selected mass populations were seeded into
Nucleic Acids Research, 2008, Vol. 36, No. 12 406924-well culture dishes and grown overnight followed by
treatment with the indicated concentrations of TSA for
further 24h. Subsequently, reporter gene activity was
assessed using the Luciferase Assay System (Promega).
Values were normalized to protein content in each sample
and divided by those obtained for the control vector con-
tainingsamples.Alltransfectionresultsarepresentedasthe
average from at least three independent experiments.
For in vivo ubiquitination assay, 293 cells were trans-
fected with 5mg Wt1 expression construct together with an
equal amount of a His-ubiquitin expression plasmid. 20h
after transfection cells were treated with lactacystine for
additional 20h.
For UBCH8 overexpression studies, 293 cells were
transfected in 6cm plates with 0.5, 1 and 2mg of a plasmid
encoding UBCH8 harboring a V5 epitope tag in absence
or presence of 1mg Wt1 expression construct. The
pcDNA3.1 plasmid transfected cells were used as a con-
trol. Cells were harvested 24h posttransfection and Wt1
levels were determined by western blot.
siRNA transfection
For UBCH8 knockdown experiments 293 cells were
seeded at 1 10
5 cells per well in a 6-well plate in 2ml
medium 1day prior to transfection. siRNA (ON-
TARGET plus SMARTpool duplex, Dharmacon,
Lafayette, Colorado, USA) directed against UBCH8 was
diluted to 100 ml in serum-free media to achieve a ﬁnal
concentration of 50nM, and 10 ml siFect Transfection
Reagent (Qiagen) was added. Samples were vortexed,
incubated at room temperature for 10min and then
added drop-wise to the cells. Twenty-four hours post-
transfection media was replaced and cells were grown
additionally for 36h, followed by incubation in presence
of 500nM TSA for 20h. Transfection without siRNA and
TSA was used as a control.
RESULTS
Differential effects of HDAC inhibitors on Wt1expression
While we were analyzing epigenetic changes at the murine
Wt1 locus in Wt1 expressing and Wt1 nonexpressing cells,
we observed a dramatic downregulation of Wt1 mRNA
levels following treatment of M15 cells with TSA. This
eﬀect was dose- and time-dependent (Figure 1A). TSA
had no eﬀect on  -Actin expression suggesting that the
eﬀect on Wt1 expression was speciﬁc and not due to cell
death. We then wanted to quantify the eﬀect and used
real-time PCR. Within 24h TSA at 100nM concentration
caused Wt1 downregulation to about 40% and at 500nM
to <5% of the original levels (Figure 1A, left). With
500nM TSA maximal reduction was reached after 12h
(Figure 1A, right).
We further analyzed whether this eﬀect was speciﬁc for
M15 cells, which express high levels of endogenous Wt1
(Figure 1E) or could be observed in other cell types. We
therefore treated the two human cell lines 293 and K562 as
well as murine TM3 cells with TSA and could observe
signiﬁcant reduction of Wt1 mRNA levels in all cell
lines tested (Figure 1B and data not shown). However,
TSA concentrations required as well as the magnitude of
the eﬀect varied between the diﬀerent cell lines. In order to
assess a possible eﬀect of TSA on cell cycle progression,
we have analyzed cell cycle distribution of TSA-treated
cells by ﬂow cytometric analysis. While M15 cells accumu-
lated in G2 phase, K562 cells showed a G1 arrest
(Supplementary Figure 1A). Thus, the eﬀect of TSA on
cell cycle did not correlate with its eﬀect on Wt1 expres-
sion. Of note, analysis of cell viability indicated a toxic
eﬀect of TSA only at a concentration of 1mM
(Supplementary Figure 1B) and conﬁrmed that the eﬀects
on Wt1 expression were not due to cell death.
To test whether TSA was unique among HDAC inhibi-
tors in that it downregulated Wt1, we included SAHA,
MS-275 and VPA in our experiments. M15 cells were
treated for 24h with various concentrations of the three
respective substances and Wt1 mRNA levels were mea-
sured by quantitative real-time PCR. In SAHA-treated
cells, Wt1 mRNA levels were strongly reduced with
increasing drug concentrations (Figure 1C, left), albeit
much higher doses than with TSA were required. In con-
trast, VPA had no signiﬁcant eﬀect on Wt1 expression
(Figure 1C, right). Acetylation of histone H4 was used
as a control for VPA activity. When we used the HDAC
inhibitor MS-275, signiﬁcant reduction in Wt1 expression
levels could be observed (Figure 1D, left); this eﬀect was
even more dramatic in K562 cells (Figure 1D, right).
These data suggest that the loss of Wt1 mRNA amount
is independent of the levels of Wt1 expression (Figure 1E);
moreover, it is a phenomenon shared by many but not all
HDAC inhibitors. TSA and SAHA inhibit both class I
and class II HDACs, whereas VPA and MS-275 have
been reported to be class I-selective (34,35). Thus, the
diﬀerential eﬀect of TSA/SAHA/MS-275 and VPA on
Wt1 gene regulation cannot be attributed to a speciﬁc
class of HDACs.
TSA downregulates Wt1at thetranscriptional level
Downregulation of Wt1 mRNA upon TSA treatment
prompted us to investigate the responsible mechanism.
One possibility could be that TSA may aﬀect the stability
of Wt1 mRNA. Alternatively, TSA could directly inﬂu-
ence Wt1 transcription. To investigate the ﬁrst possibility,
M15 cells were treated with the transcriptional inhibitor
actinomycin D 1h before the addition of TSA. Subse-
quently, steady-state Wt1 mRNA was measured by real-
time PCR. Most of the repressive eﬀect of TSA on Wt1
mRNA levels could be blocked by pretreatment with acti-
nomycin D (Figure 2A). This suggested that TSA does not
signiﬁcantly alter Wt1 mRNA stability. In order to exam-
ine whether TSA would act at the level of transcription,
we performed a nuclear run-oﬀ assay using untreated and
TSA-treated M15 cell nuclei. Already, after 3h, TSA
treatment profoundly suppressed synthesis of new Wt1
transcripts (Figure 2B and C). Longer TSA treatments
(12 and 24h) resulted in further loss in Wt1 mRNA synth-
esis. These results suggest that in response to TSA treat-
ment, Wt1 is downregulated at the transcriptional level
and that TSA has no signiﬁcant eﬀect on Wt1 mRNA
stability.
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Figure 1. HDAC inhibitors aﬀect Wt1 expression. (A) Quantitative real-time PCR of Wt1 expression in M15 cells that had been treated for 24h with
TSA at diﬀerent concentrations (left) or with 500nM TSA for diﬀerent time points (right). (B) Analysis as in (A) employing the human cell lines 293
(left) and K562 (right). (C) Analysis as in (A) using the HDAC inhibitors suberoylanilide hydroxamic acid (SAHA, left) and valproic acid (VPA,
right) and M15 cells. (D) Analysis as in (A) using the HDAC inhibitor MS-275 in M15 (left) and K562 cells (right). (E) Relative Wt1 expression in
diﬀerent cell lines was measured by quantitative real-time PCR. HDAC inhibitor treatment was done for 24h when not speciﬁed otherwise. Insets in
(A) show gel pictures of the respective RT–PCR products; the inset in (C) shows a western blot performed with an anti-acetylated histone H4
antibody to conﬁrm VPA activity. The inset in (E) shows WT1 protein levels. Bars represent  SD from three independent experiments (
 P<0.05;
  P<0.005; paired Student’s t-test).
Nucleic Acids Research, 2008, Vol. 36, No. 12 4071We then asked, whether downregulation of Wt1 expres-
sion by TSA required new protein synthesis. We therefore
pretreated M15 cells with cycloheximide to inhibit new
protein synthesis and then challenged the cells with TSA
for 20h. As shown in Figure 2D, such treatment could not
prevent TSA-dependent Wt1 mRNA downregulation.
This result supports the notion that new protein synthesis
is not needed for TSA-dependent downregulation of Wt1
expression.
To identify the TSA responsive region in the Wt1 gene, a
3.3kb Wt1 promoter fragment as well as the large introns 1
and 3 of the murine Wt1 gene (Figure 3A) were cloned into
the pGL3-Basic LUC and pGL3-Promoter LUC vectors,
respectively. These reporter gene constructs, together with
a puromycin resistance-conferring construct were trans-
fected into M15 cells, which were subsequently selected
by puromycin for 4 days. Subsequently, mass populations
were split, treated with diﬀerent concentrations of TSA
for 20h and ﬁnally luciferase activity was determined.
Under these conditions, TSA had no eﬀect on the Wt1
promoter activity (Figure 3B). At the highest concentra-
tion of 10nM, TSA treatment was found to increase the
activity of intron 1. Whether this might reﬂect a promoter
activity that has been described to reside in intron 1 of the
Wt1 gene (36) remains to be determined. In contrast,
we could observe a TSA-induced and dose-dependent
downregulation of Wt1 intron 3 activity. This eﬀect
could already be observed at the lowest concentration
used, namely 1nM. The TSA concentrations used here
were considerably lower than those required for the reduc-
tion of endogenous Wt1 expression (Figure 1A). We
assume that this might be due to diﬀerences in the genomic
context as well as in copy number of the respective frag-
ments. We conclude from these studies, that elements in
intron 3 of Wt1 are involved in the repression of Wt1
expression by HDAC inhibitors.
To characterize such a regulatory element with better
resolution, we examined epigenetic alterations within
intron 3 of the Wt1 gene in M15 cells. For this, we per-
formed chromatin immunoprecipitation using an anti-
body against acetylated histone 4 (H4) and subsequent
PCR analysis. When we used primers speciﬁc for a geno-
mic region at the 50 end of intron 3 (spanning position
688–847), we observed a decrease in acetylation of H4
upon TSA treatment (Figure 3C); this decrease was less
pronounced when primers were placed more 30 and absent
in two more downstream regions of intron 3 as well as in a
promoter fragment. We conclude from these experiments
that TSA-mediated downregulation of Wt1 expression is
associated with speciﬁc changes in histone modiﬁcation
within intron 3 of the Wt1 locus.
TSA promotes proteasomal degradation of Wt1 protein
To determine the eﬀect of TSA on Wt1 protein levels,
western blot analysis was performed. In TSA-treated
M15 cells, a signiﬁcant decrease of Wt1 protein was
observed (Figure 4A). Densitometric analysis revealed
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4072 Nucleic Acids Research, 2008, Vol. 36, No. 12that upon 4h of TSA treatment 30% protein was lost,
while after 8 and 16h 60 and 95% of Wt1 protein had
been degraded, respectively (Supplementary Figure 2A).
Surprisingly, simultaneous treatment of M15 cells with
TSA and cycloheximide attenuated TSA mediated degra-
dation of the Wt1 protein such that after 16h almost 40%
of Wt1 protein was still present. A comparable eﬀect was
obtained with SAHA, while VPA led to a more subtle
Wt1 degradation, which, however, was also reversed by
cycloheximide (Supplementary Figure 2B). Interestingly,
a signiﬁcant and cycloheximide-sensitive WT1 degrada-
tion was also detectable in human leukemic K562 cells
(Figure 4B). This observation suggested the possibility of
some kind of protease induction, responsible for Wt1
degradation.
Proteases responsible for the degradation of Wt1 have
not been reported yet. In order to examine the involve-
ment of candidate proteases in Wt1 degradation, we used
various protease inhibitors. NH4Cl is a weak base known
to inhibit lysosomal hydrolases by reducing the
acidiﬁcation of the endosomal/lysosomal compartment.
Pepstatin A is an inhibitor of acid proteases and leupeptin
inhibits serine and cysteine proteases. Application of these
protease inhibitors together with TSA did not prevent
Wt1 protein degradation (data not shown). Similarly,
addition of ALLN, ALLM and z-VAD-fmk, inhibitors
of calpain I, II and caspases, respectively, had no signiﬁ-
cant eﬀect. However, cotreatment with lactacystine, which
is a highly speciﬁc inhibitor of the 20S proteasome subunit
suppressed the TSA mediated degradation of the Wt1 pro-
tein in M15 cells (Figure 4C). After 20h of treatment, Wt1
protein levels were 3-fold higher in TSA and lactacystine-
treated cells than in the case of TSA alone (Figure 4D).
The involvement of the proteasome in Wt1 degradation
suggests that Wt1 might be ubiquitinated. We therefore
transfected cells with a Wt1 expression vector together
with a plasmid encoding a His-tagged ubiquitin molecule.
Subsequent analysis by puriﬁcation of the cell extract via
nickel chelate chromatography and western blotting
demonstrated that Wt1 is indeed ubiquitinated and that
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Nucleic Acids Research, 2008, Vol. 36, No. 12 4073this modiﬁcation can be enhanced by inhibition of the
proteasome (Figure 4E).
Ubiquitin-conjugating enzyme UBCH8 is involvedin WT1
degradation
Ubc8 (named Ubce8 in mouse and UBCH8 in humans) is
an ubiquitin-conjugating enzyme, which is 4–5-fold upreg-
ulated in F9 cells upon TSA treatment (37). In order to
analyze whether this enzyme might also be involved in
TSA-induced WT1 degradation, we investigated the
expression of UBCH8 in TSA-treated 293 cells by semi-
quantitative PCR and further quantiﬁcation by real-time
PCR in a dose-dependent manner. At a concentration of
100nM TSA, 6-fold UBCH8 induction was observed that
was further increased with 500nM and 1mM TSA after
20h (Figure 5A). A similar eﬀect was observed in M15
cells (data not shown). The increase in UBCH8 expression
was also reﬂected at the protein level (Figure 5B). Ubc8/
UBCH8 induction was not only exerted by TSA but also
by VPA as well as SAHA in M15 as well as K562 cells
(Supplementary Figure 3). To analyze whether WT1 is a
substrate of UBCH8, overexpression studies were per-
formed. The 293 cells were transiently transfected with
increasing concentrations of an UBCH8 encoding plasmid
in absence or presence of a construct encoding HA-tagged
Wt1. The levels of endogenous as well as transfected WT1
were signiﬁcantly decreased upon increasing concentra-
tions of UBCH8 (Figure 5C and D). Constant levels of
b-Actin indicated that the eﬀect on WT1 is speciﬁc and
not due to general protein degradation.
The functional signiﬁcance of UBCH8 expression levels
for WT1 degradation was further substantiated by siRNA
experiments in 293 cells. Application of a siRNA pool
against UBCH8 mRNA resulted in a dose-dependent
and signiﬁcant reduction in UBCH8 expression level
(Figure 5D). Transfection of 293 cells with UBCH8
siRNA prevented degradation of the endogenous WT1
protein upon TSA treatment (Figure 5E). These experi-
ments support the involvement of UBCH8 in the degrada-
tion of WT1 upon TSA treatment.
Thus, we conclude that in addition to an eﬀect of the
HDAC inhibitor TSA on transcription of the Wt1 gene,
TSA also leads to the induction of proteasomal degrada-
tion of WT1at the protein level. This is at least in part
mediated by induction of UBCH8 expression, which
encodes an ubiquitin-conjugating enzyme.
DISCUSSION
Conceptually, hyperacetylation of histones following inhi-
bition of HDAC activity would be predicted to promote
a general increase in gene expression. As chromatin
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4074 Nucleic Acids Research, 2008, Vol. 36, No. 12structure opens, transcription factors should gain easier
access to their cognate-binding sites, thus enhancing the
recruitment of cofactors and the basal transcription
machinery. However, treatment of cells with HDAC inhi-
bitors like TSA does not lead to a general increase in gene
expression and changes the activity state of only a limited
number of genes (24). Genes with upregulated activity
upon HDAC inhibitor treatment comprise the cell cycle
inhibitor encoding gene p21, p53 and the von Hippel–
Lindau tumor suppressor genes as well as the pro-apopto-
tic genes bax and bad (28,38–40). Conversely, a smaller
number of genes have been shown to be downregulated
by HDAC inhibitors; these include bcl-2, HIF-1 , VEGF
and p16 (28,41,42). The reasons for this selectivity are not
yet understood. In one case, HDAC inhibitor-mediated
downregulation of a particular set of genes has been
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a transcription factor, namely NF-kB p65 with the acety-
lated form of a signaling molecule, Stat1, and subsequent
reduction of p65 DNA binding (43).
We report here that the Wilms tumor suppressor gene
Wt1 also belongs to the class of genes that are downregu-
lated by HDAC inhibitors. Downregulation was observed
with TSA as well as with SAHA, both inhibitors of class I
and II HDACs. VPA, an inhibitor of class I HDACs
only (34) did not cause a reduction in Wt1 expression,
while MS-275, another class I-selective HDAC inhibitor
also downregulated Wt1 expression. The diﬀerent beha-
vior of MS-275 and VPA on Wt1 expression might be
explained by their diﬀerent biological potency (the respec-
tive EC50 values depend on the speciﬁc substrates and
diﬀer by a factor of 10
3–10
4) or by their diﬀerent target
proﬁle. It has been shown that while VPA can be classiﬁed
as a speciﬁc class I HDAC inhibitor, MS-275 is only class
I-selective and can, e.g. also eﬃciently inhibit the class II
HDAC9 (35). Thus, from these data, we cannot conclude
which speciﬁc HDACs mediate downregulation of
Wt1 mRNA. The latter was observed in the murine cell
lines M15 and TM3 as well as in human K562 and 293
cells. This indicates that reduction of Wt1 expression by
HDAC inhibitors is a general and not a cell-line-speciﬁc
phenomenon.
Strikingly, downregulation of Wt1 expression was very
rapid; within 3h of TSA treatment Wt1 mRNA was
reduced to almost 50%. This suggests that repression of
Wt1 mRNA expression is an early event and that the half-
life of Wt1 mRNA must be  3h. Mechanistically, loss of
Wt1 mRNA could be mediated by two possible mechan-
isms. First, TSA could aﬀect the rate of Wt1 transcription
or second, Wt1 mRNA stability. Our experiments employ-
ing the transcriptional (RNA polymerase) inhibitor
actinomycin D indicate that TSA has no eﬀect on Wt1
mRNA stability and downregulation of Wt1 mRNA
upon TSA treatment requires ongoing RNA synthesis.
Moreover, we were able to show by nuclear run-oﬀ
assay that TSA strongly aﬀected Wt1 transcription.
In order to explore the possible mechanisms, we inves-
tigated whether ongoing protein synthesis was required
for TSA-mediated downregulation of Wt1. For this, we
used the protein translation inhibitor cycloheximide
and observed that this inhibitor did not prevent downre-
gulation of Wt1 mRNA. Thus, Wt1 mRNA loss does not
require de novo protein synthesis. Conceivably, loss of Wt1
expression by blocking HDAC activity could be mediated
by histones or by nonhistone proteins. Increasing acetyla-
tion of histones associated with Wt1 regulatory regions
could cause the movement of nucleosomes on the Wt1
locus and thus mask critical cis-acting sites. Nucleosomes
have been shown to move and be remodeled on speciﬁc
loci, including the lysozyme gene and the IL-12p40 (44,45).
Alternatively, as a consequence of HDAC inhibition a
transcriptional activator of Wt1 expression could loose
its function or a potential repressor could be activated
as a consequence of hyperacetylation. Acetylation/deace-
tylation of several transcription factors including p53,
NF-kB, E2f1 and Stat1 have been described (43,46–48).
Further studies will be required to identify the trans-acting
factors mediating the TSA eﬀect on Wt1 expression.
We also wanted to identify the cis-element that is
responsible for the TSA eﬀect on Wt1 expression. Con-
siderable work has been done regarding the tissue- and
temporal-speciﬁc expression of Wt1; however, the Wt1
locus is remarkably complex and our knowledge of its
regulation is still quite limited. In terms of elements
regulating Wt1 expression in particular tissues, a 258bp
hematopoietic cell-speciﬁc enhancer that is located in
intron 3 and bound by GATA-1 and c-Myb has been
described (49). The same intron harbors a 460bp silencer
that represses WT1 transcription in nonrenal cells such
as leukemic (K562 and HL60) and cervical carcinoma
cells (HeLa) (50). Moreover, a construct including the
promoter, two enhancer elements located in intron 3 and
at the 30 end of the WT1 gene could induce robust expres-
sion of a reporter gene in respective transgenic leukemia
cells (51).
We reasoned that transient transfections would not be
well suited for the identiﬁcation of regulatory elements
mediating the TSA eﬀects, since the chromatin conﬁgura-
tion might not be physiological. We have therefore
employed short-term stably transfected cells for these
experiments. When we used a luciferase construct linked
to a 3.3kb Wt1 promoter fragment, TSA did not have any
eﬀect. Conversely, a reporter construct harboring intron 3
of Wt1 led to more than 60% downregulation in reporter
activity upon TSA treatment. Unexpectedly, we did see
a TSA-mediated enhancement in intron 1 stimulated
reporter gene activity. While no enhancers have been iden-
tiﬁed in intron 1 of Wt1, a promoter that controls expres-
sion of an antisense Wt1 transcript has been reported to
reside in the ﬁrst intron (36). It might be possible that
TSA exerts an eﬀect on the activity of this promoter. By
ChIP, we could also show that histones H4 in a region in
the 50 part of intron 3 are diﬀerentially acetylated in the
presence and absence of TSA, respectively. Other regions
within intron 3 did not seem to be aﬀected. This is in
agreement with the existence of a regulatory region in
intron 3 of the human WT1 locus that has been mentioned
above. Whether the sequences that respond to TSA over-
lap with the enhancer and silencer sequences in the human
WT1 gene remains to be explored.
In addition to downregulation of Wt1 mRNA, TSA also
led to enhanced degradation of the WT1 protein. This
eﬀect was at least in part mediated by the ubiquitin-
conjugating enzyme Ubc8, which has been reported to
be induced by HDAC inhibitors (36). Of note, induction
of Ubc8 could also be observed by VPA as well as
SAHA and in a variety of diﬀerent cell lines. The obser-
vation that VPA causes Ubc8 induction and subsequent
WT1 degradation, while not aﬀecting Wt1’s transcription
indicates that the two phenomena are mediated by dif-
ferent molecular mechanisms. Overexpression of UBCH8
resulted in the enhanced destabilization of both endogen-
ous and transfected WT1 protein and knockdown of
UBCH8 rescued TSA-mediated degradation of WT1.
This shows that Ubc8 is a rate-limiting factor in WT1
degradation, while the corresponding E3 ligase is not.
4076 Nucleic Acids Research, 2008, Vol. 36, No. 12This is the ﬁrst demonstration that WT1 degradation is
controlled by the proteasomal machinery.
In summary, we provide evidence that HDAC inhibi-
tors like TSA lead to a dramatic reduction of Wt1 expres-
sion, both at the level of transcription and at the protein
level. Given that WT1 levels are high not only in many
hematopoietic malignancies but also in a variety of solid
tumors, that high WT1 levels are associated with poor
prognosis, and that various cancer cells depend on high
WT1 expression levels downregulation of this protein
could be an anticancer strategy.
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